Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 351.89
DARA's Cash to Debt is ranked higher than
55% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. DARA: 351.89 )
Ranked among companies with meaningful Cash to Debt only.
DARA' s 10-Year Cash to Debt Range
Min: 0.16  Med: 402.07 Max: No Debt
Current: 351.89
Equity to Asset 0.76
DARA's Equity to Asset is ranked higher than
59% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DARA: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
DARA' s 10-Year Equity to Asset Range
Min: -0.14  Med: 0.78 Max: 0.96
Current: 0.76
-0.14
0.96
F-Score: 4
Z-Score: -5.01
M-Score: -0.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -404.84
DARA's Operating margin (%) is ranked lower than
71% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. DARA: -404.84 )
Ranked among companies with meaningful Operating margin (%) only.
DARA' s 10-Year Operating margin (%) Range
Min: -47868  Med: -2503.34 Max: 39.81
Current: -404.84
-47868
39.81
Net-margin (%) -399.41
DARA's Net-margin (%) is ranked lower than
71% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. DARA: -399.41 )
Ranked among companies with meaningful Net-margin (%) only.
DARA' s 10-Year Net-margin (%) Range
Min: -48680  Med: -3794.92 Max: 44.75
Current: -399.41
-48680
44.75
ROE (%) -67.71
DARA's ROE (%) is ranked lower than
71% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. DARA: -67.71 )
Ranked among companies with meaningful ROE (%) only.
DARA' s 10-Year ROE (%) Range
Min: -305.91  Med: -122.67 Max: 38.03
Current: -67.71
-305.91
38.03
ROA (%) -57.32
DARA's ROA (%) is ranked lower than
74% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. DARA: -57.32 )
Ranked among companies with meaningful ROA (%) only.
DARA' s 10-Year ROA (%) Range
Min: -176.71  Med: -101.27 Max: 22.08
Current: -57.32
-176.71
22.08
ROC (Joel Greenblatt) (%) -25457.67
DARA's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. DARA: -25457.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DARA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24415.58  Med: -6837.05 Max: 277.73
Current: -25457.67
-24415.58
277.73
EBITDA Growth (3Y)(%) -54.40
DARA's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. DARA: -54.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DARA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -48.55 Max: 9.3
Current: -54.4
0
9.3
EPS Growth (3Y)(%) -52.80
DARA's EPS Growth (3Y)(%) is ranked lower than
94% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. DARA: -52.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DARA' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -52.50 Max: 7.3
Current: -52.8
0
7.3
» DARA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DARA Guru Trades in Q4 2013

Jim Simons 157,175 sh (New)
» More
Q1 2014

DARA Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q4 2014

DARA Guru Trades in Q4 2014

Jim Simons 200,940 sh (New)
» More
Q1 2015

DARA Guru Trades in Q1 2015

Jim Simons 144,900 sh (-27.89%)
» More
» Details

Insider Trades

Latest Guru Trades with DARA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.59
DARA's P/B is ranked higher than
87% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. DARA: 1.59 )
Ranked among companies with meaningful P/B only.
DARA' s 10-Year P/B Range
Min: 0.02  Med: 1.20 Max: 12.6
Current: 1.59
0.02
12.6
P/S 6.54
DARA's P/S is ranked higher than
70% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. DARA: 6.54 )
Ranked among companies with meaningful P/S only.
DARA' s 10-Year P/S Range
Min: 0.43  Med: 11.90 Max: 5414.49
Current: 6.54
0.43
5414.49
Current Ratio 3.11
DARA's Current Ratio is ranked lower than
61% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. DARA: 3.11 )
Ranked among companies with meaningful Current Ratio only.
DARA' s 10-Year Current Ratio Range
Min: 0.69  Med: 5.30 Max: 25.68
Current: 3.11
0.69
25.68
Quick Ratio 3.05
DARA's Quick Ratio is ranked lower than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. DARA: 3.05 )
Ranked among companies with meaningful Quick Ratio only.
DARA' s 10-Year Quick Ratio Range
Min: 0.69  Med: 4.75 Max: 25.26
Current: 3.05
0.69
25.26
Days Inventory 139.09
DARA's Days Inventory is ranked lower than
58% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. DARA: 139.09 )
Ranked among companies with meaningful Days Inventory only.
DARA' s 10-Year Days Inventory Range
Min: 23.44  Med: 101.11 Max: 950.52
Current: 139.09
23.44
950.52
Days Sales Outstanding 88.45
DARA's Days Sales Outstanding is ranked lower than
66% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. DARA: 88.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
DARA' s 10-Year Days Sales Outstanding Range
Min: 2.49  Med: 151.58 Max: 1169.35
Current: 88.45
2.49
1169.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.78
DARA's Price/Net Cash is ranked higher than
86% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. DARA: 2.78 )
Ranked among companies with meaningful Price/Net Cash only.
DARA' s 10-Year Price/Net Cash Range
Min: 0.64  Med: 4.38 Max: 34.48
Current: 2.78
0.64
34.48
Price/Net Current Asset Value 2.41
DARA's Price/Net Current Asset Value is ranked higher than
89% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. DARA: 2.41 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DARA' s 10-Year Price/Net Current Asset Value Range
Min: 0.62  Med: 3.94 Max: 98.09
Current: 2.41
0.62
98.09
Price/Tangible Book 2.41
DARA's Price/Tangible Book is ranked higher than
81% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. DARA: 2.41 )
Ranked among companies with meaningful Price/Tangible Book only.
DARA' s 10-Year Price/Tangible Book Range
Min: 0.61  Med: 3.90 Max: 50.58
Current: 2.41
0.61
50.58
Price/Median PS Value 0.53
DARA's Price/Median PS Value is ranked higher than
87% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. DARA: 0.53 )
Ranked among companies with meaningful Price/Median PS Value only.
DARA' s 10-Year Price/Median PS Value Range
Min: 0.41  Med: 7.66 Max: 361.86
Current: 0.53
0.41
361.86
Earnings Yield (Greenblatt) (%) -126.65
DARA's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. DARA: -126.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DARA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -129.97  Med: 1138.65 Max: 337876.4
Current: -126.65
-129.97
337876.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PJUF.Germany,
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
» More Articles for DARA

Headlines

Articles On GuruFocus.com
PARA GANAR DINERO Jul 15 2012 
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 13 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 14 2010 
DARA Biosciences Inc. Reports Operating Results (10-Q) Nov 13 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) Aug 14 2009 
DARA Biosciences Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May... Jun 25 2015
Lifshitz & Miller Law Firm Announces Investigation of Bio-Reference Laboratories, Inc., DARA... Jun 16 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of DARA... Jun 11 2015
Ryan & Maniskas, LLP Investigation of DARA BioSciences, Inc. Jun 11 2015
DARA BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Jun 10 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of DARA BioSciences, Inc. of... Jun 04 2015
DARA BioSciences Announces Proposed Acquisition Agreement With Midatech Pharma PLC, a UK Based... Jun 04 2015
DARA BioSciences Announces Proposed Acquisition Agreement With Midatech Pharma PLC, a UK Based... Jun 04 2015
DARA BIOSCIENCES, INC. Financials May 22 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... May 19 2015
10-Q for DARA BioSciences, Inc. May 15 2015
DARA BioSciences Announces First Quarter 2015 Results May 13 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2015
DARA BioSciences Announces First Quarter 2015 Results May 13 2015
Q1 2015 DARA Biosciences Inc Earnings Release - After Market Close May 13 2015
DARA BioSciences Announces Date and Time for Announcement of First Quarter 2015 Results May 12 2015
DARA BioSciences Announces Date and Time for Announcement of First Quarter 2015 Results May 12 2015
Most active Nasdaq-traded stocks Apr 29 2015
Coverage initiated on DARA BioSciences by H.C. Wainwright Apr 24 2015
DARA BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK